Gilead’s Price Reduction Strategy: A Serious Move, But Not A Long-Term Model For US
“Authorized generics” for Gilead's leading hepatitis C brands stands out from prior, largely symbolic responses to the lower list prices. This is not a political move, but a business one. It is also the clearest demonstration yet of why pricing reforms are necessary if lower list prices are the policy goal.
You may also be interested in...
A subscription payment model could be a solution for high-priced drugs, Louisiana thinks – and appears to have at least one manufacturer willing to participate. Will the Trump Administration agree?
Approach has been endorsed by Express Scripts as more workable solution than trying to cut list prices for drugs already on the market.
Have pharma companies responded sufficiently to President Trump's call for “massive” price reductions?